Summit Therapeutics Inc. SEC Filings

Summit Therapeutics Inc. entered into a distribution agreement with J.P. Morgan Securities LLC allowing at the market offerings of its common stock with an aggregate offering price of up to $380,000,000. Under this arrangement, J.P. Morgan, as sales agent, may sell shares from time to time at market or negotiated prices and will receive a commission of up to 3.0% of the gross sales price per share. Summit has no obligation to sell shares and may suspend offers at any time. Any issuances will occur under its effective Form S-3 registration statement (File No. 333-296642) and a related prospectus supplement filed on July 23, 2026.

Summit Therapeutics Inc. is establishing an at-the-market equity program to issue and sell up to $380,000,000 of common stock through J.P. Morgan Securities LLC as sales agent. Shares may be sold on The Nasdaq Global Market under the symbol SMMT or through other permitted transactions, with the Sales Agent earning up to 3.0% of the gross sales price.

Assuming sales at $14.74 per share, the company illustrates issuance of 25,780,189 shares versus 793,120,362 shares outstanding as of June 30, 2026. Net tangible book value would rise from $0.79 to $1.22 per share, causing illustrative dilution of $13.52 per share to new investors. Proceeds are intended primarily to fund development of lead oncology candidate ivonescimab, including NSCLC, CRC and other solid-tumor trials, and for working capital.

Summit discloses substantial doubt about its ability to continue as a going concern because existing cash and investments do not fund 12 months of planned operations, making additional capital raises important. Recent HARMONi study data showed a hazard ratio of 0.76 for overall survival with ivonescimab and an acceptable safety profile, and Summit entered a clinical collaboration with Arcus Biosciences to evaluate ivonescimab plus casdatifan in clear cell renal cell carcinoma.

Summit Therapeutics Inc. reported a net loss of $215,700 for the three months and $405,124 for the six months ended June 30, 2026, compared with losses of $565,708 and $628,621 a year earlier. Operating expenses were $220,496 for the quarter, driven by research and development of $157,733 and general and administrative costs of $62,763. Stock-based compensation remained significant at $68,706 for the quarter, though lower than the prior-year period.

Cash used in operating activities reached $263,415 in the first half of 2026. As of June 30, 2026, cash and cash equivalents were $419,365 and short-term investments were $271,313, against an accumulated deficit of $2,699,283. Management states that this liquidity is not sufficient to fund planned operations for at least one year and that these conditions raise substantial doubt about the company’s ability to continue as a going concern, making additional financing critical.

The company’s strategy centers on ivonescimab, a bispecific PD-1/VEGF-A antibody being developed across multiple Phase III trials in non-small cell lung and colorectal cancers. In EGFR‑mutated NSCLC after EGFR-TKI therapy, the HARMONi trial showed a progression free survival hazard ratio of 0.52, while overall survival trended favorably but did not reach statistical significance. A Biologics License Application for this setting has been accepted by the FDA with a Prescription Drug User Fee Act goal action date of November 14, 2026; the FDA has cautioned that a statistically significant overall survival benefit is expected for approval.

Summit Therapeutics reported Q2 2026 results and progress on its ivonescimab program. GAAP net loss was $215.7 million, or $(0.28) per share, versus $565.7 million, or $(0.76) per share, a year earlier. Non-GAAP net loss was $147.0 million, or $(0.19) per share. Cash, cash equivalents and short-term investments were $690.7 million at June 30, 2026, compared with $713.4 million at December 31, 2025, supported by $230.8 million of Q2 gross proceeds from its ATM facility and a further $68.4 million raised afterward; the company reported no debt.

GAAP operating expenses were $220.5 million in Q2 2026, down from $568.4 million due mainly to lower stock-based compensation, while non-GAAP operating expenses rose to $151.8 million from $89.6 million as ivonescimab development expanded. For the first half of 2026, net cash used in operating activities increased to $263.4 million, partly offset by $234.9 million of cash provided by financing activities.

Summit highlighted ivonescimab as its lead asset. An updated HARMONi overall survival analysis showed a hazard ratio of 0.76 for the intent-to-treat population and for Asian and Western subgroups, with Western patients reaching 23.2 months of median follow-up and Asian patients 32.7 months. The Biologics License Application for ivonescimab plus chemotherapy in EGFR-mutated non-squamous non-small cell lung cancer has a Prescription Drug User Fee Act goal action date of November 14, 2026. In China’s HARMONi-6 Phase III trial, ivonescimab plus chemotherapy achieved an overall survival hazard ratio of 0.66 versus tislelizumab plus chemotherapy. Enrollment in the global HARMONi-3 first-line NSCLC study is complete, with key progression-free survival and interim overall survival analyses expected between the second half of 2026 and the first half of 2027. Summit also sold its ridinilazole antibiotic asset to Biossil for $500,000 upfront, up to $104.5 million in milestones, and tiered royalties, and expanded collaborations with Arcus, Revolution Medicines, GORTEC, GSK and multiple investigator-sponsored studies.

Summit Therapeutics Inc. reported updated overall survival results from its global Phase III HARMONi trial of ivonescimab plus platinum-doublet chemotherapy versus chemotherapy alone in patients with EGFR‑mutated, locally advanced or metastatic non‑squamous NSCLC previously treated with a third‑generation EGFR TKI. The study had already shown a statistically significant benefit in progression‑free survival, one of its two primary endpoints along with overall survival.

With a June 2026 data cut, a hazard ratio of 0.76 for overall survival was observed in both the full intention‑to‑treat population and the western patient subgroup, indicating a favorable survival trend compared with placebo plus chemotherapy. Earlier analyses showed hazard ratios of 0.79 at the April 2025 primary OS analysis and 0.78 at the September 2025 analysis, when median OS was 16.8 months for ivonescimab plus chemotherapy versus 14.0 months for placebo plus chemotherapy. Western follow‑up increased from 9.2 to 13.7 to 23.2 months across these analyses, while Asian patients remained locked at 32.7 months of follow‑up. Ivonescimab continued to show an acceptable, manageable safety profile consistent with prior Phase III data, with no additional safety signals. These updated OS data have been provided to the FDA, where a Biologics License Application based on HARMONi is under review with a PDUFA goal action date of November 14, 2026.

Summit Therapeutics Inc. reported results of its 2026 Annual Meeting of Stockholders held on June 10, 2026. Stockholders elected nine directors to serve until the 2027 annual meeting and ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.

Stockholders approved, on a non-binding advisory basis, the compensation of the company’s named executive officers. They also approved an amendment to the Summit Therapeutics Inc. 2020 Stock Incentive Plan to increase the number of shares of common stock issuable under the plan by 8,000,000 shares, providing additional equity for future grants.

Summit Therapeutics Inc. Co-CEO Mahkam Zanganeh reported a large indirect open-market purchase of 3,810,000 shares of Common Stock at $13.12 per share on behalf of her spouse. The filing also lists existing holdings, including 31,000 direct shares and substantial indirect stakes through family trusts and an immediate family member. A footnote states she disclaims beneficial ownership beyond her pecuniary interest.

Summit Therapeutics Inc. Co-Chief Executive Officer and director Robert W. Duggan reported an open-market purchase of 3,810,000 shares of common stock at $13.12 per share. After this transaction, he directly holds 573,883,879 shares of Summit Therapeutics common stock.

The filing also lists indirect holdings attributed to entities and individuals related to him, including 10,199,776 shares held by the Shaun Zanganeh Irrevocable Trust, 25,824,474 shares held by the Mahkam Zanganeh Revocable Trust, 31,000 shares held by his spouse, and 76,680 shares held by an immediate family member of his spouse. He disclaims beneficial ownership of these indirect holdings except to the extent of any pecuniary interest.

Summit Therapeutics Inc. has withdrawn its previously announced proposed underwritten public offering of securities, effective June 10, 2026, citing market conditions. Because the offering has been terminated, no securities will be sold under that proposed transaction. The update is provided as a Regulation FD disclosure and is not treated as a filed report for liability purposes under Section 18 of the Exchange Act.